ANEB Share Price Performance
Recent ANEB News & Updates
No updates
Anebulo Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.19
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Anebulo Pharmaceuticals, Inc. Competitors
About ANEB
- Founded
- 2020
- Employees
- 3
- CEO
- WebsiteView website
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.7%
- 1 Year: 17.5%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. As for the longer term, the market has actually risen by 18% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading